ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,520, issued on Jan. 27, was assigned to SENELIX Co. LTD. (Seoul, South Korea).
"YKL-40-targeting human monoclonal antibody" was invented by Dae Young Kim (Cheongju-si, South Korea), Kyung Jae Kang (Pohang-si, South Korea), Yoon Ji Kim (Cheongju-si, South Korea), Se Ra Lee (Sejong, South Korea) and Jin Tae Hong (Cheongju-si, South Korea).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a monoclonal antibody binding specifically to YKL-40. A high expression level of YKL-40 is associated with the proliferation and metastasis of cancer and a monoclonal antibody against YKL-40 exhibits an effect of inhibiting the proliferati...